Infusion Pharmacokinetics of Lipocurc™ (Liposomal Curcumin) and its Metabolite Tetrahydrocurcumin in Beagle Dogs

被引:0
|
作者
Helson, Lawrence [1 ]
Bolger, Gordon [2 ]
Majeed, Muhammed [3 ]
Vcelar, Brigitta [4 ]
Pucaj, Kresimir [2 ]
Matabudul, Dharmendr [2 ]
机构
[1] SignPath Pharma Inc, Quakertown, PA 18951 USA
[2] Nucro Tech, Scarborough, ON, Canada
[3] Sabinsa Corp, E Winsdor, NJ USA
[4] Polymun Sci, Klosterneuburg, Austria
关键词
Liposomal curcumin; Lipocurc (TM); tetrahydrocurcumin; infusion pharmacokinetics; TISSUE DISTRIBUTION; RATS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Curcumin's instability and its metabolite, tetrahydrocurcumin (THC) pose a major issue for the establishment of dependable pharmacokinetics and excretion profiles. Additional pharmacokinetic variances are associated with durations of intravenous infusions. We found that stabilizing curcumin with phosphoric acid allows accurate quantitative determinations of curcuminoids in the plasma and bile, by preventing degradation during the analytical processes. Two male and two females dogs were infused with Lipocurc (TM) 10 mg/kg over two hours, and another four dogs (two males and two females) were infused with Lipocurc (TM) 10 mg/kg over eight hours. Plasma levels of curcumin and THC were determined during the infusions and at necropsy. THC levels were 6.3-9.6-fold higher than curcumin during both infusion rates, suggesting a combination of a high-rate of enzymatic curcumin metabolism and a comparatively slower rate of blood THC clearance. When levels of curcumin and THC were compared during infusion durations, the two-hour infusion levels were significantly higher than the eight-hour infusion. The plasma half-lives of both compounds following the two-hour infusion ranged from 0.4-0.7 hours, and was a consequence of both hepatic and renal clearance However, at higher plasma concentrations renal excretion predominated, particularly with THC. Enhanced clearance rates were noted during eight-hour infusions, which prevented achieving a steady state. These observations suggest that for leukemias and lymphomas, the two-hour infusion may be advantageous based upon higher concentration profiles, and unstimulated clearance rates, however data on curcumin penetration into circulating hematopoietic cancer cells and efficacy data are required in order to confirm these suggestions.
引用
收藏
页码:4365 / 4370
页数:6
相关论文
共 50 条
  • [41] Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate
    Jiang, Xuemin
    Galettis, Peter
    Links, Matthew
    Mitchell, Paul L.
    McLachlan, Andrew J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (03) : 326 - 333
  • [42] A New Model to Describe the Single-dose Pharmacokinetics of Bevacizumab and Predict Its Multiple-Dose Pharmacokinetics in Beagle Dogs
    Li, Meizhen
    Qiang, Wei
    Wen, Zhou
    Li, Linling
    Wang, Lei
    Cheng, Zeneng
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (03): : 1147 - 1155
  • [43] Simultaneous determination of tofacitinib and its principal metabolite in beagle dog plasma by UPLC-MS/MS and its application in pharmacokinetics
    Wang, Qiong
    Gu, Er-min
    Bi, Yuntian
    Su, Yanding
    Tan, Wei
    Du, Xiaoxiang
    ARABIAN JOURNAL OF CHEMISTRY, 2022, 15 (01)
  • [44] Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics
    Freise, KJ
    Martín-Jiménez, T
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2006, 29 (02) : 137 - 145
  • [45] Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
    Sattar, Adeel
    Xie, Shuyu
    Huang, Lingli
    Iqbal, Zahid
    Qu, Wei
    Shabbir, Muhammad A.
    Pan, Yuanhu
    Hussain, Hafiz I.
    Chen, Dongmei
    Tao, Yanfei
    Liu, Zhenli
    Iqbal, Mujahid
    Yuan, Zonghui
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [46] Pharmacodynamics and Pharmacokinetics of Injectable Pimobendan and Its Metabolite, O-Desmethyl-Pimobendan, in Healthy Dogs
    Pichayapaiboon, Poonavit
    Tantisuwat, Lalida
    Boonpala, Pakit
    Saengklub, Nakkawee
    Boonyarattanasoonthorn, Tussapon
    Khemawoot, Phisit
    Kijtawornrat, Anusak
    FRONTIERS IN VETERINARY SCIENCE, 2021, 8
  • [47] Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs
    Hoke, JF
    Cunningham, F
    James, MK
    Muir, KT
    Hoffman, WE
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 281 (01): : 226 - 232
  • [48] PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN AFTER INTRAVENOUS AND ORAL-ADMINISTRATION OF ENROFLOXACIN IN DOGS
    KUNG, K
    RIOND, JL
    WANNER, M
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1993, 16 (04) : 462 - 468
  • [49] Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs
    Norkus, C.
    Rankin, D.
    Kukanich, B.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2015, 38 (06) : 619 - 622
  • [50] Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice
    Rajeswari A.
    Sabesan M.
    Inflammopharmacology, 2008, 16 (2) : 96 - 99